Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01366001 · ClinicalTrials.gov registry record · Phase 1
ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine
A Phase 1 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01366001 is a Phase 1 study that has completed, run by Alkermes. The registered enrollment target is 33 participants.
The verdict
NCT01366001, a Phase 1 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of ALKS33-BUP when administered to opioid-experienced cocaine abusers.
Interventions
- DRUG Placebo
- DRUG ALKS 33-BUP
- DRUG ALKS 33
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01366001
The ClinicalTrials.gov registry entry for NCT01366001 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01366001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01366001 about?
NCT01366001 is a clinical study titled "ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine". The purpose of this study is to assess the safety and tolerability of ALKS33-BUP when administered to opioid-experienced cocaine abusers.
What is the current status of trial NCT01366001?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2011-08. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01366001?
The interventions under investigation include: Placebo (DRUG), ALKS 33-BUP (DRUG), ALKS 33 (DRUG).
Who is sponsoring clinical trial NCT01366001?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.